A Post marketing surveillance study evaluating safety and efficacy of APCEDEN®, an autologous dendritic cell immunotherapy, when administered according to the prescribing information in India (APASS)

Trial Profile

A Post marketing surveillance study evaluating safety and efficacy of APCEDEN®, an autologous dendritic cell immunotherapy, when administered according to the prescribing information in India (APASS)

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Jan 2018

At a glance

  • Drugs Autologous dendritic cell immunotherapy - APAC Biotech (Primary)
  • Indications Colorectal cancer; Lung cancer; Ovarian cancer; Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors APAC Biotech
  • Most Recent Events

    • 02 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top